Bevacizumab for recurrent glioblastoma multiforme: A meta-analysis

Eric T. Wong, Shiva Gautam, Christopher Malchow, Melody Lun, Edward Pan, Steven Brem

Research output: Contribution to journalArticle

82 Citations (Scopus)

Abstract

The FDA's approval of bevacizumab for recurrent glioblastoma on May 9, 2009, was based on the significant response rate and clinical benefits seen from randomized phase II studies. Large-scale phase III data are unavailable. In an effort to determine benchmark efficacy parameters for bevacizumab and analyze its dose-response effect, the authors performed a meta-analysis of 15 studies published from 2005 to 2009, involving 548 patients with a median age of 53 years (range, 5-74 years), that used bevacizumab to treat recurrent glioblastoma. Median overall survival was 9.3 months (95% CI, 7.9-10.6 months). The respective 6-month progression-free and 6-month overall survival rates were 45% (95% CI, 34%-57%) and 76% (95% CI, 69%-84%), respectively. Median time to tumor progression was 6.1 months (95% CI, 4.2-8.1 months). The response analysis yielded a 6% complete response (95% CI, 2%-9%), 49% partial response (95% CI, 37%-61%), and 29% stable disease (95% CI, 20%-38%). No difference was seen in bevacizumab dose-response benefit between 5 mg/kg and 10 to 15 mg/kg. The efficacy benchmarks from this meta-analysis did not differ from those of the recently published randomized phase II studies. The lack of a dose-response effect would require confirmation in a prospectively conducted clinical trial.

Original languageEnglish (US)
Pages (from-to)403-407
Number of pages5
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume9
Issue number4
StatePublished - Apr 1 2011

Fingerprint

Glioblastoma
Meta-Analysis
Benchmarking
Survival Rate
Clinical Trials
Survival
Bevacizumab
Neoplasms

Keywords

  • Bevacizumab
  • Glioblastoma
  • Meta-analysis

ASJC Scopus subject areas

  • Oncology

Cite this

Bevacizumab for recurrent glioblastoma multiforme : A meta-analysis. / Wong, Eric T.; Gautam, Shiva; Malchow, Christopher; Lun, Melody; Pan, Edward; Brem, Steven.

In: JNCCN Journal of the National Comprehensive Cancer Network, Vol. 9, No. 4, 01.04.2011, p. 403-407.

Research output: Contribution to journalArticle

Wong, ET, Gautam, S, Malchow, C, Lun, M, Pan, E & Brem, S 2011, 'Bevacizumab for recurrent glioblastoma multiforme: A meta-analysis', JNCCN Journal of the National Comprehensive Cancer Network, vol. 9, no. 4, pp. 403-407.
Wong, Eric T. ; Gautam, Shiva ; Malchow, Christopher ; Lun, Melody ; Pan, Edward ; Brem, Steven. / Bevacizumab for recurrent glioblastoma multiforme : A meta-analysis. In: JNCCN Journal of the National Comprehensive Cancer Network. 2011 ; Vol. 9, No. 4. pp. 403-407.
@article{5ce4684b74a54fae8c2fec5e798bb95c,
title = "Bevacizumab for recurrent glioblastoma multiforme: A meta-analysis",
abstract = "The FDA's approval of bevacizumab for recurrent glioblastoma on May 9, 2009, was based on the significant response rate and clinical benefits seen from randomized phase II studies. Large-scale phase III data are unavailable. In an effort to determine benchmark efficacy parameters for bevacizumab and analyze its dose-response effect, the authors performed a meta-analysis of 15 studies published from 2005 to 2009, involving 548 patients with a median age of 53 years (range, 5-74 years), that used bevacizumab to treat recurrent glioblastoma. Median overall survival was 9.3 months (95{\%} CI, 7.9-10.6 months). The respective 6-month progression-free and 6-month overall survival rates were 45{\%} (95{\%} CI, 34{\%}-57{\%}) and 76{\%} (95{\%} CI, 69{\%}-84{\%}), respectively. Median time to tumor progression was 6.1 months (95{\%} CI, 4.2-8.1 months). The response analysis yielded a 6{\%} complete response (95{\%} CI, 2{\%}-9{\%}), 49{\%} partial response (95{\%} CI, 37{\%}-61{\%}), and 29{\%} stable disease (95{\%} CI, 20{\%}-38{\%}). No difference was seen in bevacizumab dose-response benefit between 5 mg/kg and 10 to 15 mg/kg. The efficacy benchmarks from this meta-analysis did not differ from those of the recently published randomized phase II studies. The lack of a dose-response effect would require confirmation in a prospectively conducted clinical trial.",
keywords = "Bevacizumab, Glioblastoma, Meta-analysis",
author = "Wong, {Eric T.} and Shiva Gautam and Christopher Malchow and Melody Lun and Edward Pan and Steven Brem",
year = "2011",
month = "4",
day = "1",
language = "English (US)",
volume = "9",
pages = "403--407",
journal = "Journal of the National Comprehensive Cancer Network : JNCCN",
issn = "1540-1405",
publisher = "Cold Spring Publishing LLC",
number = "4",

}

TY - JOUR

T1 - Bevacizumab for recurrent glioblastoma multiforme

T2 - A meta-analysis

AU - Wong, Eric T.

AU - Gautam, Shiva

AU - Malchow, Christopher

AU - Lun, Melody

AU - Pan, Edward

AU - Brem, Steven

PY - 2011/4/1

Y1 - 2011/4/1

N2 - The FDA's approval of bevacizumab for recurrent glioblastoma on May 9, 2009, was based on the significant response rate and clinical benefits seen from randomized phase II studies. Large-scale phase III data are unavailable. In an effort to determine benchmark efficacy parameters for bevacizumab and analyze its dose-response effect, the authors performed a meta-analysis of 15 studies published from 2005 to 2009, involving 548 patients with a median age of 53 years (range, 5-74 years), that used bevacizumab to treat recurrent glioblastoma. Median overall survival was 9.3 months (95% CI, 7.9-10.6 months). The respective 6-month progression-free and 6-month overall survival rates were 45% (95% CI, 34%-57%) and 76% (95% CI, 69%-84%), respectively. Median time to tumor progression was 6.1 months (95% CI, 4.2-8.1 months). The response analysis yielded a 6% complete response (95% CI, 2%-9%), 49% partial response (95% CI, 37%-61%), and 29% stable disease (95% CI, 20%-38%). No difference was seen in bevacizumab dose-response benefit between 5 mg/kg and 10 to 15 mg/kg. The efficacy benchmarks from this meta-analysis did not differ from those of the recently published randomized phase II studies. The lack of a dose-response effect would require confirmation in a prospectively conducted clinical trial.

AB - The FDA's approval of bevacizumab for recurrent glioblastoma on May 9, 2009, was based on the significant response rate and clinical benefits seen from randomized phase II studies. Large-scale phase III data are unavailable. In an effort to determine benchmark efficacy parameters for bevacizumab and analyze its dose-response effect, the authors performed a meta-analysis of 15 studies published from 2005 to 2009, involving 548 patients with a median age of 53 years (range, 5-74 years), that used bevacizumab to treat recurrent glioblastoma. Median overall survival was 9.3 months (95% CI, 7.9-10.6 months). The respective 6-month progression-free and 6-month overall survival rates were 45% (95% CI, 34%-57%) and 76% (95% CI, 69%-84%), respectively. Median time to tumor progression was 6.1 months (95% CI, 4.2-8.1 months). The response analysis yielded a 6% complete response (95% CI, 2%-9%), 49% partial response (95% CI, 37%-61%), and 29% stable disease (95% CI, 20%-38%). No difference was seen in bevacizumab dose-response benefit between 5 mg/kg and 10 to 15 mg/kg. The efficacy benchmarks from this meta-analysis did not differ from those of the recently published randomized phase II studies. The lack of a dose-response effect would require confirmation in a prospectively conducted clinical trial.

KW - Bevacizumab

KW - Glioblastoma

KW - Meta-analysis

UR - http://www.scopus.com/inward/record.url?scp=79953876016&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79953876016&partnerID=8YFLogxK

M3 - Article

C2 - 21464145

AN - SCOPUS:79953876016

VL - 9

SP - 403

EP - 407

JO - Journal of the National Comprehensive Cancer Network : JNCCN

JF - Journal of the National Comprehensive Cancer Network : JNCCN

SN - 1540-1405

IS - 4

ER -